Ocular Therapeutix, Inc. $OCUL Holdings Trimmed by Vontobel Holding Ltd.

Vontobel Holding Ltd. cut its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 90.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,628 shares of the biopharmaceutical company’s stock after selling 100,740 shares during the period. Vontobel Holding Ltd.’s holdings in Ocular Therapeutix were worth $82,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Engineers Gate Manager LP bought a new stake in shares of Ocular Therapeutix during the second quarter valued at approximately $401,000. Integrated Wealth Concepts LLC bought a new position in Ocular Therapeutix in the 2nd quarter worth approximately $51,000. NewEdge Advisors LLC raised its position in Ocular Therapeutix by 21.7% in the 2nd quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 2,979 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Ocular Therapeutix by 44.4% during the 2nd quarter. Squarepoint Ops LLC now owns 1,415,913 shares of the biopharmaceutical company’s stock worth $13,904,000 after buying an additional 435,156 shares in the last quarter. Finally, Second Line Capital LLC lifted its holdings in Ocular Therapeutix by 20.9% during the 2nd quarter. Second Line Capital LLC now owns 638,640 shares of the biopharmaceutical company’s stock worth $6,271,000 after buying an additional 110,350 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on OCUL shares. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. UBS Group assumed coverage on Ocular Therapeutix in a research report on Sunday, October 11th. They issued a “buy” rating and a $14.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.86.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $6.61 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $6.00 and a 12 month high of $16.44. The firm has a fifty day simple moving average of $9.29 and a 200 day simple moving average of $9.18. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The firm had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.20 million. During the same period in the previous year, the business earned ($0.39) EPS. The company’s revenue was down .1% compared to the same quarter last year. As a group, equities analysts expect that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 10,869 shares of Ocular Therapeutix stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $76,626.45. Following the sale, the insider owned 307,457 shares of the company’s stock, valued at approximately $2,167,571.85. The trade was a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the sale, the insider owned 254,388 shares in the company, valued at $1,793,435.40. The trade was a 3.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 62,720 shares of company stock valued at $556,247. Corporate insiders own 3.10% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.